# A Study of BMS-986490 With or Without Bevacizumab in Advanced Solid Tumors

Source: https://onco.cc/trials/nct06730750/  
OnCo record `nct06730750` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of Bevacizumab in advanced solid tumours, run by Bristol-Myers Squibb, active and no longer recruiting.

## Summary

A Study of BMS-986490 With or Without Bevacizumab in Advanced Solid Tumors is a phase 1/2 interventional study registered as NCT06730750 by Bristol-Myers Squibb, with 360 participants enrolled, started 2025-02-12 and due to reach its primary completion in 2026-09-05. Interventions recorded: BMS-986490 and Bevacizumab.

## Fields

- Kind: Trial
- Status: active
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT06730750
- Phase: 1/2
- Setting: A Phase 1/2a, Multicenter, Open-label, First in Human Study of BMS-986490 With or Without Bevacizumab in Advanced Solid Tumors
- Sponsor: Bristol-Myers Squibb
- Enrolled: 360

## Sources

- ClinicalTrials.gov NCT06730750: https://clinicaltrials.gov/study/NCT06730750

## Connected records

- cancers: [Metastatic cancer (cancer that has spread)](https://onco.cc/cancers/metastatic-cancer/)
- drugs: [Bevacizumab](https://onco.cc/drugs/bevacizumab/)
- companies: [Bristol Myers Squibb](https://onco.cc/companies/bms/)

---
JSON: https://onco.cc/api/v1/entities/nct06730750.json